UY27259A1 - Derivados de dihidro-benzo b 1, 4- diazepin-2ona como antagonistas i de mglur2 - Google Patents

Derivados de dihidro-benzo b 1, 4- diazepin-2ona como antagonistas i de mglur2

Info

Publication number
UY27259A1
UY27259A1 UY27259A UY27259A UY27259A1 UY 27259 A1 UY27259 A1 UY 27259A1 UY 27259 A UY27259 A UY 27259A UY 27259 A UY27259 A UY 27259A UY 27259 A1 UY27259 A1 UY 27259A1
Authority
UY
Uruguay
Prior art keywords
diazepin
benzo
derivatives
2ona
dihidro
Prior art date
Application number
UY27259A
Other languages
English (en)
Spanish (es)
Inventor
E Goetschi
G Adam
J Wichmann
T J Woltering
V Mutel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY27259A1 publication Critical patent/UY27259A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UY27259A 2001-04-12 2002-04-11 Derivados de dihidro-benzo b 1, 4- diazepin-2ona como antagonistas i de mglur2 UY27259A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109126 2001-04-12

Publications (1)

Publication Number Publication Date
UY27259A1 true UY27259A1 (es) 2002-10-31

Family

ID=8177127

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27259A UY27259A1 (es) 2001-04-12 2002-04-11 Derivados de dihidro-benzo b 1, 4- diazepin-2ona como antagonistas i de mglur2

Country Status (37)

Country Link
US (1) US6548495B2 (cg-RX-API-DMAC7.html)
EP (1) EP1379522B1 (cg-RX-API-DMAC7.html)
JP (1) JP4043953B2 (cg-RX-API-DMAC7.html)
KR (1) KR100566178B1 (cg-RX-API-DMAC7.html)
CN (1) CN1268626C (cg-RX-API-DMAC7.html)
AR (1) AR035456A1 (cg-RX-API-DMAC7.html)
AT (1) ATE287883T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002310912B2 (cg-RX-API-DMAC7.html)
BG (1) BG108253A (cg-RX-API-DMAC7.html)
BR (1) BR0208887A (cg-RX-API-DMAC7.html)
CA (1) CA2441771C (cg-RX-API-DMAC7.html)
CZ (1) CZ20033002A3 (cg-RX-API-DMAC7.html)
DE (1) DE60202761T2 (cg-RX-API-DMAC7.html)
DK (1) DK1379522T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP034796A (cg-RX-API-DMAC7.html)
ES (1) ES2235044T3 (cg-RX-API-DMAC7.html)
GT (1) GT200200072A (cg-RX-API-DMAC7.html)
HR (1) HRP20030791B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0400991A3 (cg-RX-API-DMAC7.html)
IL (2) IL158021A0 (cg-RX-API-DMAC7.html)
JO (1) JO2273B1 (cg-RX-API-DMAC7.html)
MA (1) MA27011A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03009317A (cg-RX-API-DMAC7.html)
MY (1) MY130369A (cg-RX-API-DMAC7.html)
NO (1) NO325300B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ528345A (cg-RX-API-DMAC7.html)
PA (1) PA8543201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20021072A1 (cg-RX-API-DMAC7.html)
PL (1) PL367086A1 (cg-RX-API-DMAC7.html)
PT (1) PT1379522E (cg-RX-API-DMAC7.html)
RU (1) RU2270197C2 (cg-RX-API-DMAC7.html)
SI (1) SI1379522T1 (cg-RX-API-DMAC7.html)
SK (1) SK13692003A3 (cg-RX-API-DMAC7.html)
UY (1) UY27259A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002083665A1 (cg-RX-API-DMAC7.html)
YU (1) YU79103A (cg-RX-API-DMAC7.html)
ZA (1) ZA200307242B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203294A3 (en) * 1999-10-15 2003-03-28 Hoffmann La Roche Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
ATE374030T1 (de) * 2003-07-25 2007-10-15 Hoffmann La Roche Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
CN101056857B (zh) 2004-11-05 2010-12-01 弗·哈夫曼-拉罗切有限公司 异烟酸衍生物的制备方法
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
KR101151993B1 (ko) 2007-04-19 2012-06-01 에프. 호프만-라 로슈 아게 다이하이드로-벤조［ｂ］［1,4］다이아제핀-2-온 설폰아미드 유도체
EP2203439B1 (en) 2007-09-14 2011-01-26 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
EP2205565B1 (en) * 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
WO2009033702A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
EP2373649B1 (en) 2008-11-28 2013-01-23 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2010130424A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,3-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
KR20150070187A (ko) 2012-10-23 2015-06-24 에프. 호프만-라 로슈 아게 자폐 장애의 치료를 위한 ｍｇｌｕ２／３ 길항제
EP2963043B1 (en) 2013-02-28 2018-05-30 Eisai R&D Management Co., Ltd. Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
EP3134089A2 (en) 2014-04-23 2017-03-01 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of intellectual disabilities
US9969726B2 (en) 2014-06-10 2018-05-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU953819A1 (ru) * 1980-08-25 1991-09-23 Физико-химический институт АН УССР 1-(Гидразинокарбонил)алкил-1,2-дигидро-3Н-1,4-бенздиазепин-2-оны, обладающие транквилизирующими и противосудорожными свойствами
MXPA02001340A (es) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
RU2259360C2 (ru) * 1999-10-15 2005-08-27 Ф.Хоффманн-Ля Рош Аг Производные бензодиазепина и лекарственное средство, их содержащее
HUP0203294A3 (en) * 1999-10-15 2003-03-28 Hoffmann La Roche Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use

Also Published As

Publication number Publication date
NZ528345A (en) 2005-04-29
MY130369A (en) 2007-06-29
EP1379522B1 (en) 2005-01-26
CN1522252A (zh) 2004-08-18
BG108253A (bg) 2005-03-31
CA2441771A1 (en) 2002-10-24
MXPA03009317A (es) 2004-02-12
DE60202761D1 (de) 2005-03-03
DE60202761T2 (de) 2006-01-12
JP4043953B2 (ja) 2008-02-06
JO2273B1 (en) 2005-04-07
JP2004525965A (ja) 2004-08-26
PE20021072A1 (es) 2002-12-07
RU2270197C2 (ru) 2006-02-20
US6548495B2 (en) 2003-04-15
ZA200307242B (en) 2004-12-16
AR035456A1 (es) 2004-05-26
EP1379522A1 (en) 2004-01-14
CZ20033002A3 (cs) 2004-03-17
AU2002310912B2 (en) 2005-06-16
WO2002083665A1 (en) 2002-10-24
NO325300B1 (no) 2008-03-25
HRP20030791A2 (en) 2005-06-30
HK1068339A1 (en) 2005-04-29
MA27011A1 (fr) 2004-12-20
CA2441771C (en) 2008-12-30
PL367086A1 (en) 2005-02-21
YU79103A (sh) 2006-05-25
HRP20030791B1 (en) 2006-06-30
CN1268626C (zh) 2006-08-09
PA8543201A1 (es) 2002-10-31
ECSP034796A (es) 2003-12-01
KR100566178B1 (ko) 2006-03-29
SK13692003A3 (sk) 2004-05-04
ATE287883T1 (de) 2005-02-15
PT1379522E (pt) 2005-05-31
DK1379522T3 (da) 2005-05-30
NO20034496L (no) 2003-10-08
RU2003130648A (ru) 2005-04-10
US20020198197A1 (en) 2002-12-26
NO20034496D0 (no) 2003-10-08
GT200200072A (es) 2003-06-19
SI1379522T1 (en) 2005-04-30
IL158021A0 (en) 2004-03-28
KR20030088502A (ko) 2003-11-19
HUP0400991A3 (en) 2009-06-29
IL158021A (en) 2010-04-15
BR0208887A (pt) 2004-06-29
ES2235044T3 (es) 2005-07-01
HUP0400991A2 (hu) 2004-08-30

Similar Documents

Publication Publication Date Title
UY27259A1 (es) Derivados de dihidro-benzo b 1, 4- diazepin-2ona como antagonistas i de mglur2
UY27258A1 (es) Derivados de dihidro-benzo b 1, 4 diazepin-2-ona como antagonistas ii mglur2
UY27654A1 (es) Derivados de dihidrobenzodiazepin-ona iii
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
SV2002000478A (es) Derivados de tiofeno utiles como anticancerosos ref. pc10795aagl/bb
PA8462401A1 (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
UY28150A1 (es) Agentes terapeuticos
UY28314A1 (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
UY27360A1 (es) Compuestos heterobicíclicos sustituídos con triamida
GT200300129A (es) Derivados de heteroarilamida benzo condensada de tienopiridinas utiles como agentes terapeuticos,composiciones farmaceuticas que incluyen a los mismos y metodo para su uso
GT199900146A (es) Derivados de 4,4-biarilpiperidina.
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
UY28144A1 (es) Agentes terapéuticos
SV2008003032A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
PA8487701A1 (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina
AR029428A1 (es) DERIVADOS DE FENIL--PIPERIDINA, TETRAHIDROPIRIDINA,-PIPERAZINA,-AZEPAN,-TETRAHIDRO-1H-AZEPINA Y DIAZEPAN SUSTITUIDOS, UNA COMPOSICIoN FARMACEUTICA Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE UNA PREPARACION FARMACEUTICA
UY27998A1 (es) Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia
ECSP066605A (es) Derivados oxazol de tetraciclina
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
UY27394A1 (es) Pedidos con actividad anti- angiogéna.
ES2188797T3 (es) Sales de n-(4-oxo-2-(1h-tetrazoil-5-il)-4h-1 benzopran-8-il)-4-(4-fenilbutoxi)benzamida.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141126